Stock Analysis Report

Executive Summary

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe.



Flawless balance sheet with reasonable growth potential.

Share Price & News

How has M1 Kliniken's share price performed over time and what events caused price changes?

Latest Share Price and Events

Market Performance

7 Day Return




DE Healthcare


DE Market

1 Year Return




DE Healthcare


DE Market

Return vs Industry: M12 exceeded the German Healthcare industry which returned -29.7% over the past year.

Return vs Market: M12 underperformed the German Market which returned 2.9% over the past year.

Share holder returns

7 Day0.4%1.6%2.8%
30 Day8.3%-5.5%-0.2%
90 Day-6.8%-10.9%0.9%
1 Year-2.2%-4.6%-28.5%-29.7%6.2%2.9%
3 Year63.4%51.6%-29.4%-32.0%18.2%8.0%
5 Yearn/a16.4%9.9%43.1%23.6%

Price Volatility Vs. Market

How volatile is M1 Kliniken's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is M1 Kliniken undervalued based on future cash flows and its price relative to the stock market?


Discount to future cash flow value

Intrinsic Value Based on Future Cash Flows

Undervalued: M12 (€12.4) is trading below our estimate of fair value (€16.87)

Significantly Undervalued: M12 is trading below fair value, but not by a significant amount.

Price Based on Earnings

PE vs Industry: M12 is poor value based on its PE Ratio (29.2x) compared to the Healthcare industry average (25.7x).

PE vs Market: M12 is poor value based on its PE Ratio (29.2x) compared to the German market (19.7x).

Price Based on Expected Growth

Low PEG Ratio: M12 is poor value based on its PEG Ratio (1.1x)

Price Based on Value of Assets

PB vs Industry: M12 is overvalued based on its PB Ratio (3.2x) compared to the DE Healthcare industry average (1.5x).

Next Steps

Future Growth

How is M1 Kliniken expected to perform in the next 1 to 3 years based on estimates from 4 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Estimates

Future Annual Growth Analysis

Earnings vs Savings Rate: M12's forecast earnings growth (27.4% per year) is above the savings rate (0.2%).

Earnings vs Market: M12's earnings (27.4% per year) are forecast to grow faster than the German market (12.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: M12's revenue (17.3% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: M12's revenue (17.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Estimates

Future Return on Equity

High Future ROE: M12's Return on Equity is forecast to be low in 3 years time (16%).

Next Steps

Past Performance

How has M1 Kliniken performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Past Earnings Growth Analysis

Earnings Trend: M12's earnings have declined by -0.7% per year over the past 5 years.

Accelerating Growth: M12's earnings growth over the past year (32.6%) exceeds its 5-year average (-0.7% per year).

Earnings vs Industry: M12 earnings growth over the past year (32.6%) exceeded the Healthcare industry 19.5%.

Return on Equity

High ROE: M12's Return on Equity (10.7%) is considered low.

Return on Assets

ROA vs Industry: M12 has a higher Return on Assets than the Healthcare industry average last year.

Return on Capital Employed

ROCE Improving: M12's Return on Capital Employed has declined over the past 3 years.

Next Steps

Financial Health

How is M1 Kliniken's financial position?

Financial Position Analysis

Short Term Liabilities: M12's short term assets (€42.5M) exceeds its short term liabilities (€5.5M)

Long Term Liabilities: M12's short term assets (42.5M) exceeds its long term liabilities (11.4M)

Debt to Equity History and Analysis

Debt Level: M12's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: M12's debt to equity ratio has reduced from 15.5% to 0.2% over the past 5 years.

Debt Coverage: M12's debt is well covered by operating cash flow (1148.9%).

Interest Coverage: M12 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Inventory Level: M12 has a high level of physical assets or inventory.

Debt Coverage by Assets: M12's debt is covered by short term assets (assets are 361.385470x debt).

Next Steps


What is M1 Kliniken's current dividend yield, its reliability and sustainability?


Expected Dividend Yield

Dividend Yield vs Market


Current dividend yield vs market & industry

Dividend Yield and Payments Analysis

Notable Dividend: M12's dividend (2.42%) is higher than the bottom 25% of dividend payers in the German market (1.46%).

High Dividend: M12's dividend (2.42%) is low compared to the top 25% of dividend payers in the German market (3.86%).

Stable Dividend: Whilst dividend payments have been stable, M12 has been paying a dividend for less than 10 years.

Growing Dividend: M12 has only been paying a dividend for 3 years, and since then payments have not increased.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (70.8%), M12's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: M12's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).

Next Steps


What is the CEO of M1 Kliniken's salary, the management and board of directors tenure and is there insider trading?


Average board tenure


Patrick Brenske 0




Mr. Patrick Brenske has been the Chief Executive Officer of MPH Mittelständische Pharma Holding AG since January 23, 2009 and has been its Member of Management Board since 2009. Mr. Brenske serves as Chief ...

Board Age and Tenure


Average Tenure

Experienced Board: M12's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Management Team

  • Walter von Horstig

    Member of Management Board

    • Tenure: 2yrs
  • Patrick Brenske

    CEO & Member of Management Board

    • Tenure: 0yrs

Board Members

  • Albert Wahl (59yo)

    Chairman of Supervisory Board

    • Tenure: 2.3yrs
  • Sabine Meck (64yo)

    Member of Supervisory Board

    • Tenure: 4.3yrs
  • Uwe Zimdars

    Deputy Chairman of Supervisory Board

    • Tenure: 2.3yrs

Company Information

M1 Kliniken AG's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: M1 Kliniken AG
  • Ticker: M12
  • Exchange: XTRA
  • Founded: 2007
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €217.000m
  • Shares outstanding: 17.50m
  • Website: https://www.m1-kliniken.de

Number of Employees


  • M1 Kliniken AG
  • Grünauer Strasse 5
  • Berlin
  • Berlin
  • 12557
  • Germany


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
M12DB (Deutsche Boerse AG)YesBearer SharesDEEURSep 2015
M12XTRA (XETRA Trading Platform)YesBearer SharesDEEURSep 2015


M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. It develops and markets pharmaceutical, medical, and medical technology products for ae ...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 23:43
End of Day Share Price2019/10/11 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)